West Pharmaceutical Services, Inc.'s Stock Analysis

West Pharmaceutical Appoints New CEO Michel Lagarde Effective August 2026

West Pharmaceutical Services, Inc. announced the retirement of Eric M. Green as President, Chief Executive Officer, and Chair of the Board, effective August 31, 2026. Michel Lagarde has been appointed to succeed him as CEO and will also join the Board of Directors. Lagarde brings extensive experience from his previous roles at Thermo Fisher Scientific and Patheon, indicating a leadership transition aimed at fostering growth and innovation within the company.

As part of Lagarde's appointment, he has entered into an employment agreement that includes an annual salary of $1,175,000 and a target annual incentive award of 125% of his salary. He will also receive long-term incentive awards valued at $8,611,111 for 2026, along with a one-time inducement equity grant worth up to $10 million. The agreement outlines severance protections and relocation requirements, ensuring a structured transition as West Pharmaceutical Services continues to deliver solutions for injectable drug administration.

Jun 01, 2026 16:32:30

West Pharmaceutical Services Reports Material Cybersecurity Incident

West Pharmaceutical Services experienced a significant cybersecurity attack on May 7, 2026, which involved data exfiltration and system encryption. The company activated its incident response protocols immediately upon detection of the intrusion on May 4, 2026, including taking affected systems offline, notifying law enforcement, and hiring external cyber-forensic experts. While core enterprise systems have been restored and critical processes have resumed at some locations, the overall timeline for complete restoration remains undetermined.

The attack has temporarily disrupted business operations globally, and the company is implementing measures to mitigate the impact of the incident. The extent of the financial implications of the cybersecurity incident is still being evaluated. West Pharmaceutical Services is committed to transparency and will provide updates as more information becomes available.

May 11, 2026 17:06:38

West Pharmaceutical Services Annual Meeting Voting Results Summary

West Pharmaceutical Services held its 2026 Annual Meeting of Shareholders virtually on May 4, 2026, with 66,193,322 shares represented, accounting for 91.83% of the 72,081,610 shares outstanding. Four proposals were voted on, including the election of eleven directors, approval of executive compensation, ratification of PricewaterhouseCoopers LLP as the independent auditor, and a shareholder proposal for an Independent Board Chair Policy.

The election of directors was successful, with all nominees elected to serve until the 2027 Annual Meeting. The advisory vote on executive compensation was approved, and the appointment of PricewaterhouseCoopers LLP as the auditor was ratified. However, the proposal for an Independent Board Chair Policy did not pass.

May 05, 2026 16:49:31

West Pharmaceutical Services Annual Meeting Voting Results Summary

West Pharmaceutical Services, Inc. held its 2026 Annual Meeting of Shareholders virtually on May 4, 2026, with 91.83% of its common stock represented. The meeting included four proposals, all of which were voted on by shareholders, with 72,081,610 shares outstanding as of February 27, 2026.

The results of the votes showed that all eleven director nominees were elected to serve until the 2027 Annual Meeting. Additionally, the advisory vote on executive compensation was approved, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year. However, the shareholder proposal for an Independent Board Chair Policy was not approved.

May 05, 2026 16:49:31

West Pharmaceutical Services Reports Strong First Quarter 2026 Results

West Pharmaceutical Services, Inc. reported net sales of $844.9 million for the first quarter of 2026, marking a 21.0% increase compared to the same period last year, with organic growth at 15.3%. Diluted earnings per share rose to $1.92, a 56.1% increase, while adjusted-diluted EPS reached $2.13, up 46.9%. The company generated operating cash flow of $89.9 million and repurchased 1.2 million shares for approximately $297.6 million during this quarter.

The company has increased its full-year 2026 net sales guidance to a range of $3.295 billion to $3.350 billion and adjusted-diluted EPS guidance to between $8.40 and $8.75. For the second quarter of 2026, net sales are expected to be between $830 million and $850 million, with reported growth anticipated at 8.3% to 10.9%. The Proprietary Products segment saw a significant increase in net sales, driven by strong demand for High-Value Product Components, contributing to 48% of total company net sales.

Apr 23, 2026 07:11:01

CEO Eric M. Green Plans Retirement Transition Announcement

West Pharmaceutical Services, Inc. announced that Eric M. Green will retire as President, Chief Executive Officer, and Chair of the Board once a successor is appointed. The Board is working with an executive recruiting firm to facilitate the search, with the transition expected in the second half of 2026. Green has served in these roles since 2015 and emphasized the importance of a smooth transition for the company’s ongoing success.

In conjunction with this announcement, the company reaffirmed its financial guidance for 2026, originally provided in February 2026. Green's tenure is noted for significant growth, including doubling the company's sales and achieving a total shareholder return of approximately 350%. West Pharmaceutical Services, a provider of injectable solutions, reported $3.07 billion in net sales for fiscal year 2025 and operates globally with over 10,000 employees.

Mar 09, 2026 16:33:25

West Pharmaceutical Services Reports 2025 Financial Results and Guidance

West Pharmaceutical Services, Inc. reported its fourth-quarter and full-year financial results for 2025, with net sales of $805.0 million in the fourth quarter, marking a 7.5% increase year-over-year, while full-year net sales reached $3.074 billion, a 6.3% increase. The company achieved fourth-quarter diluted earnings per share (EPS) of $1.82 and full-year diluted EPS of $6.79, reflecting increases of 2.2% and 1.5%, respectively. Operating cash flow for the year was $754.8 million, up 15.5%, with free cash flow rising significantly by 69.6% to $468.9 million. Additionally, the company repurchased 552,593 shares for $134.0 million during 2025.

Looking ahead, West Pharmaceutical Services provided financial guidance for 2026, projecting net sales between $3.215 billion and $3.275 billion, with expected growth rates of 4.6% to 6.5%. The company anticipates adjusted diluted EPS in the range of $7.85 to $8.20, representing growth of 7.7% to 12.5%. For the first quarter of 2026, net sales are expected to be between $770 million and $790 million, indicating reported growth of 10.3% to 13.2%. This guidance includes an estimated benefit from foreign currency exchange rates and excludes revenues from the recently sold SmartDose® 3.5mL product.

Feb 12, 2026 07:21:40

West Pharmaceutical Services Reports Third-Quarter 2025 Financial Results

West Pharmaceutical Services, Inc. announced its financial results for the third quarter of 2025, reporting net sales of $804.6 million, a 7.7% increase from the previous year, with organic growth at 5.0%. The diluted earnings per share (EPS) rose to $1.92 from $1.85 year-over-year. The company achieved double-digit growth in its High-Value Product (HVP) Components, which accounted for 48% of total sales. The Proprietary Products Segment saw a 7.7% increase in net sales, while the Contract-Manufactured Products Segment grew by 8.0% compared to the same period last year.

The company has raised its full-year 2025 net sales guidance to a range of $3.060 billion to $3.070 billion and adjusted-diluted EPS guidance to $7.06 to $7.11. Operating cash flow for the first nine months of 2025 was $503.7 million, reflecting an 8.7% increase year-over-year, while free cash flow rose significantly by 53.7% to $293.9 million. Additionally, the company repurchased 552,593 shares for $134.0 million during the same period, indicating a commitment to return value to shareholders.

Oct 23, 2025 07:15:00

West Pharmaceutical Services Announces Departure of Senior Vice President

West Pharmaceutical Services, Inc. has announced that Kimberly Banks MacKay, the Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the company. A transition period has been agreed upon, which will conclude no later than December 31, 2025, allowing for a smooth handover of responsibilities. Ms. MacKay will continue to fulfill her current duties until her departure.

The company expressed gratitude for Ms. MacKay's service and contributions during her tenure. This leadership change may impact the company's operational continuity and investor sentiment as the transition unfolds.

Sep 11, 2025 16:06:19

West Pharmaceutical Services Reports Q2 2025 Financial Results

West Pharmaceutical Services, Inc. announced its financial results for the second quarter of 2025, reporting net sales of $766.5 million, a 9.2% increase from the previous year, with organic net sales growth of 6.8%. Diluted earnings per share (EPS) rose to $1.82 from $1.51 year-over-year, while adjusted-diluted EPS increased to $1.84 from $1.52. The company updated its full-year 2025 net sales guidance to a range of $3.040 billion to $3.060 billion, up from the previous range of $2.945 billion to $2.975 billion, and adjusted-diluted EPS guidance to $6.65 to $6.85, an increase from $6.15 to $6.35.

The Proprietary Products segment saw a 10.7% increase in net sales to $619.8 million, driven by growth in High-Value Product (HVP) components. Contract-Manufactured Products segment sales rose by 3.0% to $146.7 million. The company reported operating cash flow of $306.5 million, an 8.2% increase, and free cash flow of $160.0 million, up from $92.4 million in the prior year. Additionally, West's Board of Directors approved a fourth-quarter dividend of $0.22 per share, payable on November 19, 2025.

Jul 24, 2025 07:17:23